Low-grade gliomas: an update on pathology and therapy

Low-grade gliomas (LGG) are not benign neoplasms. Patients with LGG eventually die as a consequence of this disease. Although the survival of patients with LGG is better than that of patients with higher-grade tumours, many of the treatments can produce or contribute to chronic impairment, particularly radiotherapy. Chemotherapy has emerged as a promising therapy, although definitive findings are awaited. Breakthroughs in molecular biology have improved our understanding of tumours and have led to the development of novel treatments and better prognoses. Ongoing clinical trials will help to elucidate the optimum management of patients with LGG.

[1]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[2]  B. Fisher,et al.  Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. , 1999, International journal of radiation oncology, biology, physics.

[3]  Jean-Yves Delattre,et al.  OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.

[4]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. R. Williams,et al.  The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[6]  J. Hunter,et al.  Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings , 2002, Neurology.

[7]  D. Figarella-Branger,et al.  Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. , 2003, Journal of neurosurgery.

[8]  R. Morantz Radiation Therapy in the Treatment of Cerebral Astrocytoma , 1987, Neurosurgery.

[9]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[10]  J. Jolles,et al.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.

[11]  J. Henson,et al.  Age-dependent rate of anaplastic transformation in low-grade astrocytoma , 1999, Neurology.

[12]  D. Rowitch,et al.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  I. Diamantis,et al.  Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material , 2004, Acta Neuropathologica.

[14]  J. Delattre,et al.  Neurological complications of radiotherapy and chemotherapy , 1998, Journal of Neurology.

[15]  L. Deangelis,et al.  Long-term outcome of low-grade oligodendroglioma and mixed glioma , 2000, Neurology.

[16]  H. Budka,et al.  Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: Gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma , 2004, Acta Neuropathologica.

[17]  A. Paetau,et al.  Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients , 2001, Neurology.

[18]  B. Scheithauer,et al.  Clinical Utility of Fluorescence In Situ Hybridization (FISH) in Morphologically Ambiguous Gliomas with Hybrid Oligodendroglial/Astrocytic Features , 2003, Journal of neuropathology and experimental neurology.

[19]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[20]  C. Daumas-Duport,et al.  Radiation therapy in the management of low-grade supratentorial astrocytomas. , 1989, Journal of neurosurgery.

[21]  J. Knisely,et al.  Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma , 1997, Journal of Neuro-Oncology.

[22]  Arie Perry,et al.  Pathology of low-grade gliomas: an update of emerging concepts. , 2003, Neuro-oncology.

[23]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[24]  A. Aguzzi,et al.  Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice , 1997, Oncogene.

[25]  David J Anderson,et al.  Identification of a Novel Family of Oligodendrocyte Lineage-Specific Basic Helix–Loop–Helix Transcription Factors , 2000, Neuron.

[26]  I. Whittle,et al.  Seizures in patients with supratentorial oligodendroglial tumours , 2006, Acta Neurochirurgica.

[27]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Montine,et al.  Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. , 1994, Neurosurgery.

[29]  Y. Shibamoto,et al.  Supratentorial low‐grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables , 1993, Cancer.

[30]  D. Troost,et al.  5-Year survival and clinical prognostic factors in progressive supratentorial diffuse “low-grade” astrocytoma: A retrospective analysis of 46 cases , 2005, Acta Neurochirurgica.

[31]  Melissa Bondy,et al.  Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.

[32]  W. Huk,et al.  Supratentorial Low-Grade Glioma: Results and Prognostic Factors Following Postoperative Radiotherapy , 1999, Strahlentherapie und Onkologie.

[33]  M. Taphoorn,et al.  Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas , 2001, Neurology.

[34]  K. Skullerud,et al.  Prevalence and prognostic significance of epilepsy in patients with gliomas. , 1998, European journal of cancer.

[35]  M. Strawderman,et al.  MIB-1 Proliferation Index Predicts Survival among Patients with Grade II Astrocytoma , 1998, Journal of neuropathology and experimental neurology.

[36]  Y. Yonekawa,et al.  Role of gemistocytes in astrocytoma progression. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[37]  C. Fuller,et al.  Fluorescence In Situ Hybridization (FISH) in Diagnostic and Investigative Neuropathology , 2002, Brain pathology.

[38]  G. Fuller,et al.  Genetic Modeling of Glioma Formation in Mice , 2002, Brain pathology.

[39]  Karlyne M. Reilly,et al.  Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum , 2002, Oncogene.

[40]  M. Faist,et al.  Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas , 1997, Cancer.

[41]  D. Nelson,et al.  White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02) , 1994, Cancer.

[42]  M. Berger,et al.  The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas , 1994, Cancer.

[43]  I. Fried,et al.  Low-grade astrocytomas may arise from different astrocyte lineages. , 1993, Neurosurgery.

[44]  J. Burbach,et al.  Somatic mutations in the brain: relationship to aging? , 1995, Mutation research.

[45]  P. Scheltens,et al.  Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma , 2002, Neurology.

[46]  S. Kollias,et al.  Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme , 2004, Journal of Neuro-Oncology.

[47]  Allan H Friedman,et al.  Phase II trial of temozolomide in patients with progressive low-grade glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Robert B. Jenkins,et al.  Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections , 2001, Modern Pathology.

[49]  G. Barnett,et al.  Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results , 2003, Journal of Neuro-Oncology.

[50]  G. Broggi,et al.  Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal. , 1994, Neurosurgery.

[51]  D. Louis,et al.  Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.

[52]  Y. Yonekawa,et al.  p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas , 2001, Brain pathology.

[53]  H. Kurzen,et al.  Inhibition of angiogenesis by non-toxic doses of temozolomide , 2003, Anti-cancer drugs.

[54]  M. Taphoorn,et al.  Delayed Radiation Toxicity after Focal or Whole Brain Radiotherapy for Low-Grade Glioma , 2004, Journal of Neuro-Oncology.

[55]  Susan M. Chang,et al.  Age and the risk of anaplasia in magnetic resonance‐nonenhancing supratentorial cerebral tumors , 1997, Cancer.

[56]  J. Villemure,et al.  Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era , 1996, Journal of Neuro-Oncology.

[57]  D. Spencer,et al.  Low-grade gliomas of chronic epilepsy: A distinct clinical and pathological entity , 1997, Journal of Neuro-Oncology.

[58]  R. Makuch,et al.  Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. , 1996, Neurosurgery.

[59]  P. Kleihues,et al.  p53 mutations in nonastrocytic human brain tumors. , 1991, Cancer research.

[60]  T. H. van der Kwast,et al.  Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas , 1990, Cancer.

[61]  D. Gutmann,et al.  Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.

[62]  A. Karim,et al.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. , 1996, International journal of radiation oncology, biology, physics.

[63]  W F Taylor,et al.  Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. , 1984, Journal of neurosurgery.

[64]  K. Fulling,et al.  The value of radiation therapy in addition to surgery for astrocytomas of the adult cerebrum , 1985, Cancer.

[65]  B. Scheithauer,et al.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  B A Kall,et al.  Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. , 1987, Mayo Clinic proceedings.

[67]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  K Takakura,et al.  Subacute brain atrophy after radiation therapy for malignant brain tumor , 1989, Cancer.

[69]  M. Strawderman,et al.  Proliferation index is related to patient age in glioblastoma , 2001, Neurology.

[70]  David N Louis,et al.  Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.

[71]  A. Gregor,et al.  Radiotherapy for malignant glioma , 1996, BMJ.

[72]  Laurent Capelle,et al.  Preferential brain locations of low‐grade gliomas , 2004, Cancer.

[73]  M. Prados,et al.  Gemistocytic astrocytomas: a reappraisal. , 1991, Journal of neurosurgery.

[74]  A. Bricolo,et al.  Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. , 1995, Surgical neurology.

[75]  S. Ashley,et al.  Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  V. Levin,et al.  Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  L D Lunsford,et al.  Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. , 1993, Journal of neurosurgery.

[78]  L. Recht,et al.  Suspected low‐grade glioma: Is deferring treatment safe? , 1992, Annals of neurology.

[79]  B. Scheithauer,et al.  Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.

[80]  S. Clemenceau,et al.  Supratentorial low-grade astrocytomas in adults. , 1993, Neurosurgery.

[81]  M. Middleton,et al.  Temozolomide: a novel oral alkylating agent , 2001, Expert review of anticancer therapy.

[82]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Twijnstra,et al.  Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2 , 2002, Genes, chromosomes & cancer.

[84]  C. Duyckaerts,et al.  Dementia Following Treatment of Brain Tumors with Radiotherapy Administered Alone or in Combination with Nitrosourea-based Chemotherapy: A Clinical and Pathological Study , 2004, Journal of Neuro-Oncology.

[85]  D. Kondziolka,et al.  Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients , 2001, Neurology.

[86]  D. Louis,et al.  Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.

[87]  T E Schultheiss,et al.  Radiation response of the central nervous system. , 1995, International journal of radiation oncology, biology, physics.

[88]  M. Berger,et al.  Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. , 2001, Journal of neurosurgery.

[89]  B. Scheithauer,et al.  Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[91]  R. Soffietti,et al.  PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. , 1998, Neurosurgery.

[92]  B. Jeremic,et al.  Radiation Therapy for Incompletely Resected Supratentorial Low-grade Glioma in Adults , 2001, Journal of Neuro-Oncology.

[93]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[94]  J. Delattre,et al.  A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. , 1996, International journal of radiation oncology, biology, physics.

[95]  G. Krol,et al.  Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.

[96]  H. Morris,et al.  Coexistence of Neoplasia and Cortical Dysplasia in Patients Presenting with Seizures , 1993, Epilepsia.

[97]  A. Cianciulli,et al.  Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[98]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[99]  Philippe Cornu,et al.  Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. , 2002, International journal of radiation oncology, biology, physics.

[100]  C. Avezaat,et al.  Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery , 1998, Journal of neurology, neurosurgery, and psychiatry.

[101]  M. Selch,et al.  Management of oligodendrogliomas. , 1993, Radiology.

[102]  Desmond Curran,et al.  Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844) , 1998 .

[103]  S B Green,et al.  The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  R. Gonzalez,et al.  MRI in treatment of adult gliomas. , 2005, The Lancet. Oncology.

[105]  M. J. van den Bent,et al.  Successful treatment of low‐grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine , 2005, Cancer.

[106]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  K. Hoang-Xuan,et al.  OLIG‐1 and 2 gene expression and oligodendroglial tumours , 2002, Neuropathology and applied neurobiology.

[108]  M. J. van den Bent,et al.  Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[109]  S. Coons,et al.  The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. , 1997, Neurosurgery.

[110]  Joanne Chan,et al.  Sonic Hedgehog–Regulated Oligodendrocyte Lineage Genes Encoding bHLH Proteins in the Mammalian Central Nervous System , 2000, Neuron.

[111]  G. Fuller,et al.  Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. , 2000, The American journal of pathology.

[112]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.